<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816812</url>
  </required_header>
  <id_info>
    <org_study_id>IBD-FITT_1</org_study_id>
    <nct_id>NCT04816812</nct_id>
  </id_info>
  <brief_title>The IBD-FITT Study - Moderate-intensity Exercise for IBD Patients With Moderate Disease Activity</brief_title>
  <acronym>IBD-FITT</acronym>
  <official_title>The IBD-FITT Study - Moderate-intensity Exercise for Patients With Inflammatory Bowel Disease With Moderate Disease Activity: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate whether exercise therapy during 12 weeks including a&#xD;
      lesson on general healthy lifestyle in adult patients with a moderately active disease is&#xD;
      more effective, compared to control patients only receiving a lesson on general healthy&#xD;
      lifestyle recommendations. The three main categories of outcomes are 1) health-related&#xD;
      quality of life, 2) general health status of the patients 3) explorative outcomes. The&#xD;
      primary outcome is health-related quality of life, the secondary outcome is general health&#xD;
      status measured by waist circumference, disease activity scores, blood pressure, and blood&#xD;
      lipids, and the third outcome are explorative outcomes (none-disease specific quality of life&#xD;
      scores, biomarkers of C-reactive protein, fecal calprotectin and immunology markers including&#xD;
      interleukins).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will apply a superior trial design in this randomized clinical trial with&#xD;
      two arms, intervention and comparison. In both the intervention and comparison arm, the&#xD;
      patients will receive the proper and usual medical treatment decided by their responsible&#xD;
      physician and changes in the medical treatment is allowed at all times.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The investigators will apply a superior trial design in this randomized clinical trial with two arms, intervention, and comparison.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Health-related quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General health - Waist circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>Waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health - blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health - Lipid</measure>
    <time_frame>12 weeks</time_frame>
    <description>Lipid status:&#xD;
i. Low-density lipoprotein (LDL) ii. High-density lipoprotein (HDL) iii. Triglycerides iv. Total cholesterol v. Hemoglobin A (Hbac1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health - Clinical disease activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Harvey Bradshaw Index (Crohn's disease) Simple Clinical Colitis Activity Index (Ulcerative colitis)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Explorative - European Quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>European Quality of life (EQ5D)</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative - Biomarkers</measure>
    <time_frame>12 weeks</time_frame>
    <description>i. Fecal calprotectin ii. C-reactive protein iii. Immunology (cytokines)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the intervention arm, a 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparison</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise intervention</intervention_name>
    <description>A 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level. This includes two supervised exercise sessions of 60 minutes per week, combined with one weekly home training session. The type of exercise is planned by a physiotherapist to fit each patient during sessions. We monitor the intervention by training diaries including frequency, intensity, time, and type of exercise (FITT) and the verbal BORG 15-point scale and heart rate monitors. We will also monitor the overall seven days' physical activity level by accelerometry using the AX3 device from the company Axivity at weeks 0 and 12.</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle - online lesson intervention</intervention_name>
    <description>The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.</description>
    <arm_group_label>Comparison</arm_group_label>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with moderately active Crohn's disease or ulcerative colitis are defined by&#xD;
             fulfilling all the following five criteria:&#xD;
&#xD;
               1. Well-characterized Crohn's disease or ulcerative colitis (physician assessment)&#xD;
                  i. Fulfilling standard clinical, endoscopic, radiologic, and histological&#xD;
                  criteria&#xD;
&#xD;
               2. A minimum of one-year disease duration from the time of diagnosis of Crohn's&#xD;
                  disease or ulcerative colitis to inclusion into the trial&#xD;
&#xD;
               3. Any of the following pharmacological treatments in a period of three months prior&#xD;
                  to inclusion:&#xD;
&#xD;
                  i. Usage of 5-Aminosalicylic acid (5-ASA) ii. Usage of corticosteroids iii.&#xD;
                  Immunomodulators usage: Azathioprine (AZA), 6-mercaptopurine (6-MP), Methotrexate&#xD;
                  (MTX) iv. Biologics usage: Anti-TNFÎ± (Infliximab, Adalimumab, Golimumab),&#xD;
                  Ustekinumab or Anti-integrin (Vedolizumab)&#xD;
&#xD;
               4. Disease activity defined by clinical disease score:&#xD;
&#xD;
                  i. Harvey Bradshaw Index (HBI) 27 &gt; 5 ii. Simple Clinical Colitis Activity Index&#xD;
                  (SCCAI) 29 &gt; 5&#xD;
&#xD;
               5. Marker for gastrointestinal inflammation:&#xD;
&#xD;
                  i. Fecal calprotectin (FC) &gt; 200 mg/g&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  1. A language barrier that prohibits the exercise instructors/supervisors to give&#xD;
             sufficient or safe instructions during the intervention or at the general health&#xD;
             lesson.&#xD;
&#xD;
             2. Known heart condition that prevents them to actively participate safely in the&#xD;
             exercise intervention.&#xD;
&#xD;
             3. Known pregnancy or planned pregnancy. 4. Disabling musculoskeletal injuries that&#xD;
             prevent them to actively participate in the exercise intervention.&#xD;
&#xD;
             5. Severe disease activity manifested clinically and with the need for urgent change&#xD;
             in treatment evaluated by the responsible physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Lund, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital &amp; University of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ken Lund, PhD</last_name>
    <phone>+45 2115 3599</phone>
    <email>ken.lund@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Southwest Jutland</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Ken Lund, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Ken Lund, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Elia J, Kane S. Adult Inflammatory Bowel Disease, Physical Rehabilitation, and Structured Exercise. Inflamm Bowel Dis. 2018 Nov 29;24(12):2543-2549. doi: 10.1093/ibd/izy199. Review.</citation>
    <PMID>29850914</PMID>
  </reference>
  <reference>
    <citation>Shephard RJ. The Case for Increased Physical Activity in Chronic Inflammatory Bowel Disease: A Brief Review. Int J Sports Med. 2016 Jun;37(7):505-15. doi: 10.1055/s-0042-103157. Epub 2016 Apr 26. Review.</citation>
    <PMID>27116344</PMID>
  </reference>
  <reference>
    <citation>Eckert KG, Abbasi-Neureither I, KÃ¶ppel M, Huber G. Structured physical activity interventions as a complementary therapy for patients with inflammatory bowel disease - a scoping review and practical implications. BMC Gastroenterol. 2019 Jul 2;19(1):115. doi: 10.1186/s12876-019-1034-9. Review.</citation>
    <PMID>31266461</PMID>
  </reference>
  <reference>
    <citation>Bilski J, Mazur-Bialy A, Brzozowski B, Magierowski M, Zahradnik-Bilska J, WÃ³jcik D, Magierowska K, Kwiecien S, Mach T, Brzozowski T. Can exercise affect the course of inflammatory bowel disease? Experimental and clinical evidence. Pharmacol Rep. 2016 Aug;68(4):827-36. doi: 10.1016/j.pharep.2016.04.009. Epub 2016 May 2. Review.</citation>
    <PMID>27255494</PMID>
  </reference>
  <reference>
    <citation>Reed JL, Pipe AL. Practical Approaches to Prescribing Physical Activity and Monitoring Exercise Intensity. Can J Cardiol. 2016 Apr;32(4):514-22. doi: 10.1016/j.cjca.2015.12.024. Epub 2015 Dec 29. Review.</citation>
    <PMID>26897182</PMID>
  </reference>
  <reference>
    <citation>Bandholm T, Christensen R, Thorborg K, Treweek S, Henriksen M. Preparing for what the reporting checklists will not tell you: the PREPARE Trial guide for planning clinical research to avoid research waste. Br J Sports Med. 2017 Oct;51(20):1494-1501. doi: 10.1136/bjsports-2017-097527. Epub 2017 Sep 7.</citation>
    <PMID>28882839</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Ken Lund</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

